Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | LSS | P48449 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3657036 | 0.98 | KDM4E (0.67) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL3367452 | 0.94 | KDM4E (0.70) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL56571 | 0.90 | KEAP1 (0.67) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL9671156 | 0.89 | KDM4E (0.83) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| Hydrochloric Acid SCHEMBL3570082 | 0.88 | KEAP1 (0.65) | KDM4EALDH1A1SMN1; SMN2HRH3KEAP1 | |
| Hydrochloric Acid SCHEMBL56159 | 0.88 | KEAP1 (0.65) | KDM4EALDH1A1SMN1; SMN2HRH3KEAP1 | |
| SCHEMBL14547108 | 0.83 | KEAP1 (0.54) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL19026551 | 0.82 | HRH3 (0.77) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL2022333 | 0.82 | KCNH2 (0.56) | KDM4EALDH1A1SMN1; SMN2HRH3KEAP1 | |
| SCHEMBL8226392 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HRH3LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081789-A | Pyrazole derivative with antitumor activity and preparation method and application thereof | 天津匠新致成科技有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-3388435-B1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | PROGENRA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3390370-B1 | BIS-TRIAZOLE COMPOUNDS WITH ANTI-BIOFILM AND ANTI-CORROSION PROPERTIES | UNIV DE TOULON (FR) | 2021-02-03 | — | — | EP | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018160944-A1 | AZOLE COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE USP7 INHIBITORS | PROGENRA, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| WO-2018090939-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | 上海瑛派药业有限公司 | 2018-05-24 | — | — | WO | disclosed |
| EP-1732543-B1 | TETRACYCLIC CARBOLINE DERATIVES FOR INHIBITING ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2961750-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D]PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | Amgen Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
| CN-1303374-A | Substituted indolinones, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-07-11 | — | — | CN | disclosed |
| EP-1100779-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-1999062882-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-09 | — | — | WO | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
| US-3994900-A | 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | USP7, USP1, USP2 | KDM4E 513/4885ALDH1A1 2210/4885SMN1; SMN2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.